Opportunity for Manager, Clinical Data Management @ PPD Pharmaceuticals
PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 32 countries and more than 9,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients
Post: Manager, Clinical Data Management - Bangalore-115615

DelCure LifeSciences Ltd. (DLL) is a full scale pharmaceutical company with an aim to bring differentiated high quality products through international collaboration with innovator companies from the USA, Switzerland, and European countries. High quality products are assured from our manufacturing partner of high repute.
Health Management and Research Institute is a registered non-profit organization based in Hyderabad, Andhra Pradesh. HMRI is supported by Piramal Foundation. and works towards making healthcare accessible, affordable and available to all segments of the population, especially those most vulnerable. In order to achieve this goal, HMRI leverages cutting edge information and communication technologies to cut costs without compromising quality as well as public-private partnerships to scale its solutions throughout India and beyond.
The Drugs and Cosmetics Rules, 1945 (D&C rules) were amended vide Drugs and Cosmetics (Fourth Amendment) Rules, 2013 published under Gazette notification G.S.R. 588(E) dated 30.08.2013 regarding the inclusion of Schedule H1 under the D&C rules containing certain antibiotics, anti-TB drugs and habit forming drugs. The notification states that these rules will come into force after six months of their publication in the official Gazette i.e. from 1st March, 2014
Indian health ministry revoked the ban from Analgin, potent analgesic and antipyretic. Last year in June 2013, government issued a ban on manufacturing and selling of analgin in country because it is involved in risk to human beings and whereas safer alternatives of analgin are available. After revoking ban from pioglitazone, this is the second time when ministry has lifted ban from a drug.
Bristol-Myers Squibb Company and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) approved a Supplemental New Drug Application (sNDA) for Eliquis (apixaban) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.
